The BRAF inhibitor vemurafenib increases survival in people with melanomas that have BRAFV600E mutations. But vemurafenib can also have side effects, including another kind of skin cancer called squamous cell carcinoma (SCC). A new Annals of Oncology study assessed the side effects of 42 people who were treated with vemurafenib and found that 26% had SCC. Other side effects included rashes, light sensitivity, and lesions on the hands and feet. The researchers recommend that doctors measure the symptoms of these adverse reactions and that patients avoid the sun.